IRADIMED CORPORATION
IRMDHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring. At a $1.10B market cap, IRADIMED CORPORATION ranks as a small-cap company within healthcare. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Market Cap
$1.10B
Beta
0.91
P/E (TTM)
49.04
P/E (Fwd)
34.98
EPS (TTM)
$1.75
EPS (Fwd)
$2.45
ROE
23.5%
ROA
15.6%
Cash
$59.1M
Total Debt
$0
Free CF
$16.2M
52W Change
9.4%
Annual Financials
Cash vs Debt
Where IRMD stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, IRMD finished 1.11% below its 150-day moving average ($90.84) and 3.39% below its 200-day moving average ($92.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRMD overbought or oversold?
At the October 15, 2026 close, IRMD's RSI(14) was 71.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
IRADIMED CORPORATION reports $59.1M in cash and $0 in total debt. Free cash flow comes in at $16.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 23.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 15.6% further supports the picture of efficient asset utilization. Revenue has grown from $53.3M (2022) to $83.8M (2025), reflecting a 57% increase over the period.
As with any equity investment, IRMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IRMD.